Clinical Trials | NRG-GY038: A Randomized Phase II Trial of Sacituzumab Govitecan-HZIY (SG) and Bevacizumab Versus Standard of Care Carboplatin, Pegylated Liposomal Doxorubicin (PLD) and Bevacizumab in Patients with Platinum-Sensitive Ovarian Cancer That Has Progressed on Prior Maintenance PARP Inhibitor Therapy

The University of Virginia seeks women age 18 years and older for a clinical trial. You may be eligible for this trial if you have high grade serous or endometrioid epithelial ovarian cancer that is platinum sensitive. This study aims to evaluate a medication called Sacituzumab Govitecan-HZIY (SG) compared to standard of care Carboplatin, PLD (pegylated liposomal doxorubicin) and Bevacizumab. If you participate in this study, you will be randomized (assigned by chance) to one of two arms: Arm 1: you will receive carboplatin intravenously (IV) and bevacizumab intravenously (IV) Arm 2: you will receive SG intravenously (IV) over 1-3 hours and bevacizumab intravenously (IV) This study will include: echocardiogram (ECHO) or multigated acquisition scan (MUGA), blood draws, tumor imaging assessments, and physical examinations. Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance. More information can be found here: https://clinicaltrials.gov/study/NCT07504588